Medical Innovations

Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation

Annonce événementielle au sens de l’art. 53 RCExercice entier

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis continues to grow with further core margin expansion and achieves important innovation milestones

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineOncologyMedical InnovationsCancerAd Hoc
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint1. Topline results showed a significant proportion of patients treated with iptacopan (200 mg twice daily…

Reimagine MedicineMedical InnovationsInnovation
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer

Basel, December 13, 2022 — Novartis today announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy. Pluvicto® is approved in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III APPLY-PNH trial1. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the investigational oral monotherapy iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5…

Reimagine MedicineMedical InnovationsInnovation
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe

Annonce événementielle au sens de l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe

Annonce événementielle au sens de l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc